Features

Features FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic communications environment.

Features Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Features Private View: Discussing Women's Health

Private View: Discussing Women's Health

Dan Chichester, chief creative officer, LLNS

Features Think you own your brand? Think again

Think you own your brand? Think again

When you have a successful brand, you tamper with it at your peril

Features We've only just begun

We've only just begun

We cemented our credibility during the most difficult period for publishing

Features Headliner: Galderma CEO confronts challenges

Headliner: Galderma CEO confronts challenges

Stuart Raetzman, CEO, Galderma Labs

Features DDR on DTC: Linzess

DDR on DTC: Linzess

Linzess has been enhanced and reworked to reach self-identified sufferers with its own brand relief story

Features Washington Insider: When FDA overstates its case

Washington Insider: When FDA overstates its case

What happens when it's the FDA—not a medical marketer—that is doing the overstating?

Features Saying goodbye to brand standards manuals

Saying goodbye to brand standards manuals

Don't waste another minute or dollar on your brand standards manual. It's painfully irrelevant

Email Newsletters